Patients with these mutational markers exhibit a higher tumor mutational burden (TMB), a well-established marker correlated with improved survival in NSCLC patients treated with PD-1 plus CTLA-4 blockade [53, 54]. This evidence concerns the gene CTLA4 and neoplasm.